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ABSTRACT. Objective. Associations between the use of micronutrient supplements (MS) and disease activity,
quality of life (QOL), and healthcare resource utilization were studied in a Canadian population of
patients with systemic lupus erythematosus (SLE).
Methods. QOL was assessed by the Medical Outcomes Study 36-item Short Form. Healthcare
resource utilization and disease activity/damage were determined.
Results. Of the 259 subjects studied, 53% were MS users and 34% used only calcium/vitamin D. MS
users had a higher Systemic Lupus International Collaborating Clinics score and utilized more
healthcare resources. Disease activity and QOL were similar between MS users and nonusers.
Conclusion. MS are frequently used by patients with SLE and are not associated with concomitant
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Health Canada1 reported that 7 in 10 Canadians have used a
complementary/alternative medicine (CAM), and micronu-
trient supplements (MS) were the most commonly used, by
57%. In rheumatic diseases including systemic lupus ery-
thematosus (SLE), the use of CAM is higher, ranging from
40%–94%2-4. Vitamin D/calcium supplements are com-
monly used, as they are often prescribed by physicians to
patients taking steroids. Despite the frequent use of CAM,
most patients did not inform their physician, and physi-
cians do not often ask about the use of supplements5,6. This
could be of concern since in some cases, using supple-
ments may present a health risk. The purpose of this study
was to determine the prevalence of MS use among
Canadian patients with SLE and the relationship of MS use
to quality of life (QOL), disease activity, and healthcare
resource utilization.
MATERIALS AND METHODS
The current use of MS was reported by 259 patients (meeting at least 4 of
the American College of Rheumatology diagnostic criteria for SLE) from 4
centers across Canada from 2003 to 2009. MS users were those taking any
vitamin/mineral in the month prior to the study enrollment.
Disease activity was assessed by the Systemic Lupus Activity Measure
(SLAM-R) and SLE Disease Activity Index 2000 (SLEDAI 2K). Scores of
SLAM-R > 7 and SLEDAI 2K > 6 were indicative of an active disease7.
Disease damage in 12 organ systems accrued since the diagnosis of SLE
was evaluated using the Systemic Lupus International Collaborating
Clinics (SLICC)7 index.
Health status was assessed based on patient self-reports on a scale of
1–5 (1 = excellent; 5 = poor). QOL was assessed using the Medical
Outcomes Study 36-item Short Form (SF-36)8. This instrument allows for
calculation of normalized scores for physical (physical component summa-
ry; PCS) and mental function (mental component summary; MCS). Scores
< 48 are considered impaired.
Utilization of healthcare professionals, diagnostic tests, hospitaliza-
tions, and use of alternative treatments over the preceding month were eval-
uated using a portion of a validated questionnaire9.
RESULTS
Mean diagnosis age of patients with SLE was 29.3 years.
Active disease existed in 23%–28%, 35% were between the
ages of 18 and 34 years, 93.4% were women, 76.4% had
completed high school, 54% were employed, 38% were
smokers, 48% were White-non-Hispanic, and 66% per-
ceived their health status as good/excellent (Table 1).
MS was used by 53%, and 34% used only vitamin D/cal-
cium supplements. The median (interquartile range) daily
dose for calcium and vitamin D was 112.5 mg (35–800 mg)
and 200 IU (35–800 IU), respectively. Multivitamins (16%),
folic acid (1%), vitamins B6 (7%), B complex (8%), B12
(2%), C (1%), and E (3%); and minerals iron (9.2%), mag-
nesium (1%), and potassium (1%) were among the other sup-
plements used. Education level, gender, disease duration, and
ethnicity had no influence on the use of supplements.
Disease activity was similar between the 2 groups (MS
users vs nonusers; Table 2). After excluding subjects taking
only calcium/vitamin D, MS users had a significantly lower
SLAM score. However, the SLICC score was higher in MS
users compared to nonusers.
Perceived health status was more impaired in MS users
regardless of the inclusion/exclusion of those taking only
vitamin D/calcium (Table 2). MCS and PCS were similar but
impaired in both groups. MS users were more likely to visit
healthcare professionals and use diagnostic tests (Table 3).
DISCUSSION
MS was used by 53% of patients with SLE, which is in line
with rates of utilization reported for the general Canadian
population1 and consistent with previous studies in rheumat-
ic diseases including SLE that have reported a prevalence
ranging from 16% to 94%2-4,10,11. However, Moore, et al4
reported a 50% prevalence of CAM use among 707 North
Americans/Europeans, but a much lower prevalence
(5%–6%) of megavitamin supplements use. This discrepancy
could be because they did not include subjects taking miner-
al supplements and/or calcium/vitamin D. Vitamin D/calcium
was the most commonly used supplement in this study. This
likely reflects the standard of care for those who are receiving
steroids and may not be considered CAM. However, calci-
um/vitamin D supplements are also commonly used by the
general population and so it is difficult to know whether they
were used as CAM or were prescribed by a physician in this
study. Thus, we conducted the analyses with and without
inclusion of those taking calcium/vitamin D.
Practice of complementary treatments is the highest
among people with chronic diseases such as those with
rheumatic diseases, in which Western allopathic medical
approaches still result in incurability, persisting pain, and
metabolic complications12-14. These patients seek alterna-
tive treatments to alleviate symptoms and improve their
QOL. However, in this study and consistent with other stud-
ies4,10, QOL was not different between MS users and
nonusers. SLAM, a disease activity measure based on
patient perception, was lower in MS users after excluding
those taking calcium/vitamin D. Yet MS users tended to
have higher cumulative damage levels. Because of the
cross-sectional design of this study, it is difficult to know
whether unsatisfactory outcomes from conventional thera-
pies caused the patients to use MS or whether the supple-
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Table 1. Characteristics of the study participants.
Characteristics % (n = 259)
Gender
Female 93 (n = 242)
Male 7 (n = 17)
Age, yrs
18–34 35 (n = 89)
35–44 23 (n = 58)
45–54 19 (n = 50)
55–64 15 (n = 40)
> 65 9 (n = 22)
Ethnicity
Hispanic 1 (n = 3)
White (non-Hispanic) 48 (n = 123)
Asian 15 (n = 38)
Aboriginal 2 (n = 4)
Others 15 (n = 40)
No answer 20 (n = 51)
Education
Some/completed elementary 17 (n = 44)
Completed high school or more 76 (n = 198)
Missing 7 (n = 17)
Currently employed 54 (n = 140)
BMI, kg/m2 26.2 ± 0.45
Normal (18–26) 63
Underweight (< 18) 3
Overweight (27–29) 12
Obese (> 30) 22
Alcoholic beverages (number/wk)
< 1 51 (n = 132)
1-6 26 (n = 67)
≥ 7 2 (n = 4)
Missing 22 (n = 56)
SLE duration, yrs 13.0 ± 0.7
ACR criteria 5.8 ± 0.1
SLAM (range 0–86) 4.8 ± 0.2
≥ 7 23 (n = 60)
SLEDAI (range 0–105) 5.3 ± 0.3
> 6 28 (n = 73)
SLICC 1.4 ± 0.1
0 39 (n = 100)
≥ 1 61 (n = 159)
Perceived health status
Poor 8 (n = 20)
Fair 27 (n = 69)
Good 41 (n = 107)
Very good/excellent 24 (n = 63)
Results are reported as percentage or mean ± SEM. BMI: body mass index;
SLE: systemic lupus erythematosus; ACR: American College of
Rheumatology; SLAM: Systemic Lupus Activity Measure; SLEDAI: SLE
Disease Activity Index; SLICC: Systemic Lupus International
Collaborating Clinics.
ment itself, or the possibility that the supplements were of
low quality, interfered with the therapeutic effect and/or
increased the toxicity of conventional treatments.
Of concern is that 70% of patients do not consult a physi-
cian before initiating the CAM therapy5,6. Under the current
law, vitamins, supplements, and herbs do not have to be eval-
uated by any regulatory agency prior to their sale. This leaves
the consumer with little or no meaningful information about
potential benefits, side effects, or adverse drug interactions.
In our study, health services were utilized more by MS
users, consistent with the findings of Moore, et al4, report-
ing 24% higher direct medical costs for CAM users than
nonusers. Although cause and effect cannot be determined
in this study, there appears to be no differences in objective
measures between users and nonusers that would explain the
higher use of conventional medical resources. This may be
a manifestation of general care-seeking behavior, which
leads to an increased consumption of both conventional and
nonconventional healthcare resources.
These data should be interpreted with caution since we
surveyed only patients who chose to receive care in a con-
ventional setting and were more likely to complete the sur-
vey. Our results could underestimate the use of MS, since
those who chose CAM as their only method or option for
SLE treatment were not included.
Micronutrient supplements are used commonly by
patients with SLE. Unfortunately, our cross-sectional data
do not allow us to discern a pattern differentiating users and
nonusers in terms of disease activity and/or QOL. Since
nutritional supplements are not regulated, both patients and
physicians will benefit from education strategies regarding
the use of CAM.
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Table 2. Disease activity and health status of users and nonusers of micronutrient supplements.
Measure Users, n = 137 Nonusers, n = 122 p
SLAM-R 4.6 ± 0.3 5.0 ± 0.3 0.25
SLEDAI-2K 5.2 ± 0.5 5.4 ± 0.5 0.75
SLICC 1.6 ± 0.2 1.2 ± 0.1 0.02
Disease duration, yrs 13.5 ± 1.1 12.4 ± 1.0 0.43
General health (1 = excellent—5 = poor) 3.3 ± 0.08 3.0 ± 0.09 0.007
PCS (≤ 48 = impaired) 38.1 ± 1.1 40.0 ± 1.1 0.21
MCS (≤ 48 = impaired) 46.9 ± 1.0 47.3 ± 1.0 0.76
Excluding those taking calcium/vitamin D n = 48 n = 122
SLAM-R 4.0 ± 0.4 5.0 ± 0.3 0.042
SLEDAI-2K 5.0 ± 0.7 5.4 ± 0.5 0.67
SLICC 1.6 ± 0.3 1.2 ± 0.1 0.092
Disease duration, yrs 11.2 ± 1.4 12.4 ± 1.0 0.48
General health (1 = excellent—5 = poor) 3.3 ± 0.1 3.0 ± 0.09 0.057
PCS (≤ 48 = impaired) 38.8 ± 1.9 40.0 ± 1.1 0.57
MCS (≤ 48 = Impaired) 46.2 ± 1.7 47.3 ± 1.0 0.56
Results are reported as mean ± SEM. p < 0.05 considered statistically significant. SLAM: System Lupus Activity
Measure; SLEDAI: SLE Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics;
MCS: mental component scores; PCS: physical component scores.
Table 3. Healthcare resource utilization among users and nonusers of micronutrient supplements.
Resource use Users, n = 137 Nonusers, n = 122 p
Visits to healthcare professionals (% of respondents) 86.0 75.2 0.027
Excluding those taking calcium/vitamin D 95.8 75.2 0.002
Number of visits to healthcare professionals 2.35 ± 0.22 2.28 ± 0.25 0.831
Excluding those taking calcium/vitamin D 2.75 ± 0.40 2.28 ± 0.25 0.324
Use of diagnostic tests (% of respondents) 77.8 63.3 0.011
Excluding those taking calcium/vitamin D 85.1 63.3 0.006
Number of diagnostic tests 2.18 ± 0.21 1.85 ± 0.23 0.298
Excluding those taking calcium/vitamin D 2.58 = 0.36 1.85 ± 0.23 0.091
Hospital emergency visits (% of respondents) 5.9 8.3 0.45
Excluding those taking calcium/vitamin D 6.2 8.3 0.66
Results are reported as mean ± SEM or percentage. Chi-square test and unpaired t-test was used for group com-
parison. P , 0.05 considered statistically significant.
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